window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 26, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

CS014

  • Clinical & Regulatory,Therapeutic Areas

    Rare Disease Day 2026: Cereno Scientific advances disease-modifying therapies in PAH

    As Rare Disease Day 2026 shines a spotlight on patients [...]

    May 5, 2026
  • Clinical & Regulatory,Therapeutic Areas

    Cereno Scientific broadens CS014 development focus to pulmonary hypertension linked to interstitial lung disease

    Cereno Scientific has broadened the clinical development focus of its [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Cereno Scientific publishes first peer-reviewed data on HDAC inhibitor CS014 showing antithrombotic effects without bleeding risk

    Cereno Scientific has published the first peer-reviewed paper describing its [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Remepy and Merck KGaA partner on hybrid drug programmes
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Digital & Data, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • RxLogix launches AI pharmacovigilance platform for adverse event monitoring
    Categories: Clinical & Regulatory, Digital & Data, Drug Discovery & Development
  • Intellia reports first positive Phase 3 in vivo CRISPR data in hereditary angioedema
    Categories: Advanced Therapies, Clinical & Regulatory, Drug Discovery & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top